Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway

Dan Jin(Binzhou Medical University), Jiwei Guo(Binzhou Medical University)

Oncology Reports

June 12, 2018

10.3892/or.2018.6486

Cited by 21

Related Papers

Neuropeptide Substance P Improves Osteoblastic and Angiogenic Differentiation Capacity of Bone Marrow Stem Cells<i>In Vitro</i>

|BioMed Research International|2014|56

Repression of YAP by NCTD disrupts NSCLC progression

|Oncotarget|2016|52

RETRACTED: The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC

|EBioMedicine|2018|52

Synergistic Effects of Chemotherapy and Phototherapy on Ovarian Cancer Using Follicle-Stimulating Hormone Receptor-Mediated Liposomes Co-Loaded with SN38 and IR820

|Preprints.org|2024|1